A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
